Clinical trials: Age Factor
Offensive Aggression, Sexual Aggression
A Brief Intervention to Prevent Adolescent Dating Aggression Perpetration
The proposed study is a test of the feasibility and preliminary efficacy of a brief motivational interview style intervention. The intervention will take place in the pediatric emergency department of the Boston University…
- Conditions
- Offensive Aggression, Sexual Aggression, Dating Violence Perpetration and Victimization
- Trial name
- PLR (NCT02080923)
- Testing
- Brief Motivational Interview
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Boston University
Subfoveal Choroidal Neovascularization (CNV), Secondary to Age-related Macular Degeneration (AMD)
Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
This extension study will investigate the long-term safety and tolerability of multiple intravitreal injections of ranibizumab administered to patients with subfoveal choroidal neovascularization secondary to age-related macular…
- Trial name
- NCT00504959
- Testing
- ranibizumab
- Where
- 36 sites in Australia, Belgium and 8 more
- Volunteers
- 234 people
- Sponsor
- Novartis
Dry Age-related Macular Degeneration, Detachment of the Posterior Hyaloid
Posterior Macular Adhesion: A Potential Risk Factor for Non-exudative Age Related Macular Degeneration (AMD) to Develop Exudative AMD
Choroidal neovascularisation in age related macular degeneration is one of the major causes of legal blindness in the western world existing in two major occurences, the dry and the wet form.The etiology of age related macular…
- Trial name
- PAM (NCT00926861)
- Testing
- ultrasound, OCT
- Where
- Austria
- Volunteers
- 320 people
- Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
to Compare LIF Level in Cord Blood of Embryo's That Are IUGR to Those That Are AGA
Leukemia Inhibitory Factor Level in Intrauterine Growth Restriction Neonates
To see if there is a relationship between the level of LIF in IUGR fetuses and compared to the level of LIF in AGA fetuses
- Trial name
- NCT02518126
- Testing
- blood sample and tissue sample
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Neovascular Age-related Macular Degeneration, Macular Degeneration
Photodynamic Therapy for PDA in NV AMD
The purpose of this prospective observational study is to assess the potential clinical effects of adjunctive verteporfin photodynamic therapy (PDT) for persistent disease activity among patients with neovascular age-related…
- Trial name
- NCT02452840
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Duke University
Cognitive Decline
Cohort Study of Risk Factors for Postoperative Cognitive Decline
Presently, the role of either genetic factors or biological sex in the development of postoperative cognitive dysfunction (POCD) is unknown.
- Trial name
- POCD (NCT03676738)
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Oregon Health and Science University
Age Related Macular Degeneration
A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）
A randomized, double-blind, parallel controlled, multicenter clinical trial to compare the efficacy and safety of LY09004 and EYLEA in the Treatment of Wet Age-related Macular Degeneration（wAMD)
- Trial name
- NCT04572698
- Testing
- LY09004, Eylea
- Volunteers
- 416 people
- Sponsor
- Luye Pharma Group Ltd.
Age Related Macular Degeneration
Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients
To demonstrate the effects of Lucentis (ranibizumab), Avastin ( bevacizumab), and Eylea ( aflibercept) on the levels of naturally occurring Vascular Endothelial Growth Factor (VEGF) in the systemic circulation of Age Related…
- Trial name
- NCT02296567
- Testing
- Ranibizumab, Bevacizumab, Aflibercept
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- East Florida Eye Institute
Macular Degeneration, Regional Blood Flow
The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion
Age related macula degeneration is one of the most common sight threatening diseases of the elderly. The so called wet form of AMD is caused by choroidal neovascularisation (CNV) of pathological vessels, which lead to leakage…
- Conditions
- Macular Degeneration, Regional Blood Flow, Vascular Endothelial Growth Factor
- Trial name
- NCT00709657
- Testing
- ranibizumab, bevacizumab or pegaptanib
- Where
- Austria
- Volunteers
- 8 people
- Sponsor
- Medical University of Vienna
Age-Related Macular Degeneration
Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy
This study is to investigate whether there is an association of the LOC387715/HTRA1 and vascular endothelial growth factor polymorphism with response to treatment with intravitreal ranibizumab injections for patients with…
- Trial name
- NCT01233128
- Where
- South Korea
- Volunteers
- 121 people
- Sponsor
- Kyungpook National University Hospital
Age-related Macular Degeneration
Head to Head Study of Anti-VEGF Treatment.
An exploratory single site, open label, randomized, controlled study evaluated plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab (Lucentis) and conbercept (Langmu) for neovascular…
- Trial name
- RELIANCE (NCT02577107)
- Testing
- ranibizumab, Conbercept
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vasculitis
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice.
- Trial name
- NCT06769412
- Testing
- aflibercept 2 mg
- Where
- United States
- Volunteers
- 550,000 people
- Sponsor
- Regeneron Pharmaceuticals
Exudative Age-related Macular Degeneration
Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept
The purpose of this study is to examine the plasma concentration of vascular endothelial growth factor (VEGF) after standard treatment with one of the newest growth factor inhibitors, aflibercept (Eylea).
- Trial name
- Eylea-2014 (NCT02125864)
- Testing
- intravitreal injection
- Volunteers
- 16 people
- Sponsor
- Oslo University Hospital
Age-Related Macular Degeneration
The Role of Complement Factor H Polymorphism in the Regulation of Choroidal Vascular Tone in Young Healthy Subjects
Age related macular degeneration (AMD) is a multifactorial disease with a strong genetic component. Given that it is known that impaired regulation of choroidal vascular tone is present in patients with AMD, the current study…
- Trial name
- NCT02102880
- Testing
- the polymerase chain reaction (PCR)
- Where
- Austria
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Age-related Macular Degeneration
Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization
This is a pilot, prospective, interventional, case-control study investigating aqueous levels of vascular endothelial growth factor (VEGF) in eyes with AMD-related neovascularization treated with intravitreal bevacizumab at the…
- Trial name
- NCT01350323
- Testing
- Aqueous sample
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- University of Molise
Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Rupture
The BEAR III Trial for Bridge-Enhanced ACL (Anterior Cruciate Ligament) Restoration
Bridge-Enhanced ACL Restoration (BEAR) is a new procedure being developed to treat patients with ACL injuries. In the BEAR procedure, an implant is placed between the torn ends of the ACL and the patient's own blood is added to…
- Trial name
- NCT03348995
- Testing
- Bridge-Enhanced ACL Restoration (BEAR)
- Where
- 11 sites in United States
- Volunteers
- 250 people
- Sponsor
- Miach Orthopaedics
Autistic Disorder, Pervasive Developmental Disorder
Advanced Grandparental Age as a Risk Factor for Autism
The Division of Medical Genetics at the University of Mississippi Medical Center is recruiting parents of children with a pervasive developmental disorder (including autism, autistic spectrum disorder, PDD-NOS, Asperger syndrome…
- Conditions
- Autistic Disorder, Pervasive Developmental Disorder, Asperger Syndrome, Childhood Disintegrative Disorder
- Trial name
- NCT00464477
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Mississippi Medical Center
Abortion, Legal
Maternal and Fetal Adrenocorticotropic Hormone (ACTH) and Leukemia Inhibitory Factor (LIF) and Gestational Age
In 2010, Simamura et al have demonstrated in a rat model that one of the pro-inflammatory cytokine belonging to the Interleukin-6 family cytokines, LIF, is required for the proliferation of neuronal progenitor cells in the…
- Trial name
- NCT03231904
- Testing
- Blood test
- Volunteers
- 50 people
- Sponsor
- Rambam Health Care Campus
Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
The study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with Anti-VEGF treatment vs. Anti-VEGF alone (with sham dexamethasone injection) in patients with subfoveal choroidal neovascularization…
- Trial name
- NCT00511706
- Testing
- dexamethasone, ranibizumab
- Where
- 9 sites in United States, Australia and 7 more
- Volunteers
- 243 people
- Sponsor
- Allergan
Wet Macular Degeneration
Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to…
- Trial name
- NCT02541084
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 72 people
- Sponsor
- Bayer